JP2020521794A - 胆管癌の治療のためのｆｇｆｒ２阻害剤 - Google Patents

胆管癌の治療のためのｆｇｆｒ２阻害剤 Download PDF

Info

Publication number
JP2020521794A
JP2020521794A JP2019566178A JP2019566178A JP2020521794A JP 2020521794 A JP2020521794 A JP 2020521794A JP 2019566178 A JP2019566178 A JP 2019566178A JP 2019566178 A JP2019566178 A JP 2019566178A JP 2020521794 A JP2020521794 A JP 2020521794A
Authority
JP
Japan
Prior art keywords
fgfr
fgfr2
patient
acid
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019566178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521794A5 (enExample
Inventor
ブッソラーリ，ジャクリーヌ，シリーロ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2020521794A publication Critical patent/JP2020521794A/ja
Publication of JP2020521794A5 publication Critical patent/JP2020521794A5/ja
Priority to JP2023077882A priority Critical patent/JP2023113650A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019566178A 2017-06-02 2018-06-01 胆管癌の治療のためのｆｇｆｒ２阻害剤 Withdrawn JP2020521794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077882A JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのｆｇｆｒ２阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17174295 2017-06-02
EP17174295.0 2017-06-02
EP18171315.7 2018-05-08
EP18171315 2018-05-08
PCT/EP2018/064523 WO2018220206A1 (en) 2017-06-02 2018-06-01 Fgfr2 inhibitors for the treatment of cholangiocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077882A Division JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのｆｇｆｒ２阻害剤

Publications (2)

Publication Number Publication Date
JP2020521794A true JP2020521794A (ja) 2020-07-27
JP2020521794A5 JP2020521794A5 (enExample) 2021-07-26

Family

ID=62555054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566178A Withdrawn JP2020521794A (ja) 2017-06-02 2018-06-01 胆管癌の治療のためのｆｇｆｒ２阻害剤
JP2023077882A Pending JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのｆｇｆｒ２阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077882A Pending JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのｆｇｆｒ２阻害剤

Country Status (16)

Country Link
US (2) US11707463B2 (enExample)
EP (1) EP3634414A1 (enExample)
JP (2) JP2020521794A (enExample)
KR (1) KR20200010505A (enExample)
CN (1) CN111050769A (enExample)
AU (1) AU2018278271B2 (enExample)
BR (1) BR112019025056A2 (enExample)
CA (1) CA3064317A1 (enExample)
IL (1) IL271058A (enExample)
JO (1) JOP20190280A1 (enExample)
MA (1) MA49248A (enExample)
MX (1) MX2019014366A (enExample)
MY (1) MY204203A (enExample)
PH (1) PH12019502710A1 (enExample)
UA (1) UA126478C2 (enExample)
WO (1) WO2018220206A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370099B (es) 2014-03-26 2019-12-02 Astex Therapeutics Ltd Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
WO2020165181A1 (en) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Cancer treatment
US20220054484A1 (en) * 2019-03-29 2022-02-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP2022534742A (ja) * 2019-05-28 2022-08-03 キューイーディー セラピューティクス，インコーポレイテッド 胆管癌を治療するための方法
WO2021023178A1 (zh) * 2019-08-05 2021-02-11 江苏恒瑞医药股份有限公司 一种吡咯并六元杂环化合物在制备治疗fgfr2基因变异的肿瘤的药物中的用途
CN114945367A (zh) * 2020-01-17 2022-08-26 贝达医药公司 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1904480A2 (en) 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
JP2010525301A (ja) * 2007-03-23 2010-07-22 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 子宮内膜癌および前癌の診断、分類および治療の方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
EP3939614A1 (en) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
LT3198033T (lt) 2014-09-26 2022-05-10 Janssen Pharmaceutica Nv Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi
AU2016341445B2 (en) 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CYTOKINE AND GROWTH FACTOR REVIEWS, vol. 26(4), JPN6022024413, 2015, pages 425 - 449, ISSN: 0005088711 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 32(15_suppl), JPN6022024414, 2014, pages 2501, ISSN: 0005088712 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 35(15_suppl), JPN6022024412, 30 May 2017 (2017-05-30), pages 4074, ISSN: 0005088710 *

Also Published As

Publication number Publication date
MA49248A (fr) 2020-04-15
MX2019014366A (es) 2020-07-27
CN111050769A (zh) 2020-04-21
CA3064317A1 (en) 2018-12-06
EP3634414A1 (en) 2020-04-15
WO2018220206A1 (en) 2018-12-06
AU2018278271B2 (en) 2024-07-04
US20240016801A1 (en) 2024-01-18
AU2018278271A1 (en) 2019-12-05
BR112019025056A2 (pt) 2020-06-16
JOP20190280A1 (ar) 2019-12-02
KR20200010505A (ko) 2020-01-30
MY204203A (en) 2024-08-15
PH12019502710A1 (en) 2020-06-08
US12350266B2 (en) 2025-07-08
JP2023113650A (ja) 2023-08-16
IL271058A (en) 2020-01-30
US20200138809A1 (en) 2020-05-07
US11707463B2 (en) 2023-07-25
UA126478C2 (uk) 2022-10-12

Similar Documents

Publication Publication Date Title
US12350266B2 (en) FGFR2 inhibitors for the treatment of cholangiocarcinoma
TWI816881B (zh) 用於治療三陰性乳癌之組合療法
RU2715236C2 (ru) Комбинации
CN106211755A (zh) 使用erk和raf抑制剂的组合的癌症治疗
JP2023022190A (ja) 癌治療
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
CN108135892A (zh) 用于治疗癌症的mdm2抑制剂的给药方案
EP3923942A1 (en) Cancer treatment
JP7761485B2 (ja) 胆管癌の処置
EA043608B1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
HK40051490A (en) Treatment of cholangiocarcinoma
TW202313038A (zh) 用於治療晚期實性瘤之ｆｇｆｒ酪胺酸激酶抑制劑
HK40029054A (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
CN117320724A (zh) 用于治疗晚期实体瘤的fgfr酪氨酸激酶抑制剂
US20220054484A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2025090966A1 (en) Mek inhibitors, alone or in combination with cdk4/5 inhibitors, for use in treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230623

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230713